fenofibrate has been researched along with acipimox in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chojnowska-Jezierska, J; Jabłoński, S; Tkaczewski, W | 1 |
| Cutfield, WS; Gluckman, PD; Hofman, PL; Lobie, PE; Vickers, MH | 1 |
3 other study(ies) available for fenofibrate and acipimox
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Clinical effectiveness of acipimox and fenofibrate in patients with hyperlipoproteinemia type II].
Topics: Adult; Aged; Cholesterol; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Treatment Outcome | 1993 |
Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat.
Topics: Animals; Birth Weight; Blood Pressure; Bone Development; Fatty Acids, Nonesterified; Female; Fenofibrate; Growth; Growth Hormone; Hematocrit; Hypolipidemic Agents; Insulin; Insulin-Like Growth Factor I; Liver; Male; Organ Size; Pregnancy; Pyrazines; Rats; Rats, Wistar; Tibia; Weight Gain | 2006 |